Lonza acquires Simbiosys Biowares' preclinical cell and molecular biology group

Saturday, 21 November, 2009 | Supplied by: Capsugel Australia Pty Ltd


Lonza has completed the acquisition of the preclinical cell and molecular biology assets of Simbiosys Biowares India, a biology outsourcing company, expanding its cell-biology platform.

Simbiosys’s cell and molecular biology group specialises in primary cell isolation and tissue sourcing and in performing preclinical services to mid-size pharmaceutical companies.

Simbiosys Biowares India offers preclinical services in the areas of: drug discovery services (includes lead validation and lead development using in-vitro and in-vivo ADME-Tox assays); molecular biology contract research services (including DNA amplification and cloning, DNA/RNA isolation, synthetic gene construction and quantitative PCR); biopharmaceutical services (includes process design optimisation of fermentation technology for producing small-molecules, proteins and mAbs for therapeutic, diagnostic and research applications).

Online: lonzabioscience.com.au
Phone: 1300 657508
Related Products

Cayman Chemical Cellular Metabolism Screening Library

Cayman Chemical's Cellular Metabolism Screening Library consists of two plates and contains...

Navinci Diagnostics NaveniFlex Cell Red proximity ligation assay kit

Optimised for cell samples, the kit enables fluorescence visualisation of protein–protein...

Lonza TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium

The products provide researchers and manufacturers with high-performance, scalable and...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd